Company

China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises

CompanyDrug

HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study

CompanyDrug

NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review

CompanyDrug

Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne

CompanyPolicy / Regulatory

NHSA Cracks Down on Price Gouging in Basic Medical Insurance Scheme

Company

FibroGen’s Roxadustat Sales in China Rise Despite Price Cut

CompanyDrug

Inmagene and HutchMed Dose First Subject in IMG-004 Phase I Study

Company

Zai Lab’s Q2 2022 Financials Show Revenue Growth and R&D Cost Cut

CompanyDrug

BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study

CompanyDrug

Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial

CompanyDrug

Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study

CompanyDeals

Hansoh Pharma Licenses TiumBio’s TU2670 for Endometriosis Treatment in Greater China